Over
the last two years, four doctors led by Dr Jeffrey Bradstreet have
eradicated autism using GcMAF in 15% of children and improved 70%.
Another 15% did not respond.
St
Peter Port, Guernsey (April 3, 2013) -- Yesterday, April 2, was
World Autism Awareness Day. Over the last two years, four doctors led
by Dr Jeffrey Bradstreet have eradicated autism using GcMAF in 15% of
children and improved 70%. Another 15% did not respond.
GcMAF
is a vital part of the human immune system that does not function
without it. However, many viruses attempt to prevent production of
the body's own GcMAF. If successful, this collapses the immune
system, resulting in the infections growing unchecked. Immuno Biotech
extracts and isolates GcMAF molecules that can then be injected to
restore the body's level of GcMAF to normal so that it can fight
infections naturally. The quality of Immuno Biotech's GcMAF and their
exhaustive testing has made it the World's leading supplier and the
provider of choice for doctors and scientists with the company being
cited in eleven research papers to date.
David
Noakes, Immuno Biotech's CEO, explained, "Dr Bradstreet used the
nagalase and other tests to prove that 85% of autistic children had
high levels of viruses and a compromised immune system. He did a
study of 1500 autistic children and gave them weekly injections of
our GcMAF. 70% of the children responded to the treatment with
reduced symptoms, and an another 15% made full recoveries. Further
trials around the world are coming up with identical results. The
reduction of autistic symptoms is permanent provided that GcMAF has
been taken for long enough for the body to start to produce its own
GcMAF at normal levels, typically 24 weeks, but first results are
usually seen inside 8 weeks."
Dr.
Jeff Bradstreet MD is an internationally recognized researcher in
autism (http://www.drbradstreet.org)
and will be presenting his latest finding on the effects of GcMAF on
autism at the world's first GcMAF conference, which will be held on
the 19th, 20th and 21st of April in Frankfurt, Germany. Presentations
by leading scientists and doctors from around the world will report
on their exceptional results with case histories. Details can be
found at http://gcmafconference.org/.
Currently there are over 60 research papers on GcMAF by 142 eminent
scientists with new peer-reviewed papers being added at an increasing
rate from university teams and doctors from dozens of countries. Many
of the independent research papers on GcMAF are listed on
http://www.gcmaf.eu.
Background
A
weekly injection of a tiny clear drop restores the level of GcMAF to
normal, effectively one millionth of a blood transfusion. That
enables the body's own immune system to fight the disease, with the
only occasional side effects being mild, cold-like symptoms as the
immune system wakes up. The time it takes to fight the infection and
return to producing normal levels of its own GcMAF depends on the
severity of the infection or cancer. An eight week course costs €660
including shipping so a typical 24 week course costs under €2000.
Immuno Biotech has supplied 4,000 patients through 300 doctors in 30
nations.
Immuno
Biotech Contact: Beate Keisa, Immuno Biotech Ltd., Tel: 0044 7781
411737, Web: http://www.gcmaf.eu
and click "contact" at the top to email.
No comments:
Post a Comment